Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GH-002 by GH Research for Treatment Resistant Depression: Likelihood of Approval
GH-002 is under clinical development by GH Research and currently in Phase I for Treatment Resistant Depression. According to GlobalData,...
GH-002 by GH Research for Unspecified Neurologic Disorders: Likelihood of Approval
GH-002 is under clinical development by GH Research and currently in Phase I for Unspecified Neurologic Disorders. According to GlobalData,...
Mebufotenin by GH Research for Unspecified Psychiatric Disorders: Likelihood of Approval
Mebufotenin is under clinical development by GH Research and currently in Phase I for Unspecified Psychiatric Disorders. According to GlobalData,...
GH-002 by GH Research for Treatment Resistant Depression: Likelihood of Approval
GH-002 is under clinical development by GH Research and currently in Phase I for Treatment Resistant Depression. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of GH Research's Mebufotenin?
Mebufotenin is a small molecule commercialized by GH Research, with a leading Phase II program in Treatment Resistant Depression. According...